KR100964604B1 - 산소 친화도가 높은 개질된 헤모글로빈을 포함하는 산소 전달용 조성물 및 방법 - Google Patents
산소 친화도가 높은 개질된 헤모글로빈을 포함하는 산소 전달용 조성물 및 방법 Download PDFInfo
- Publication number
- KR100964604B1 KR100964604B1 KR1020047010847A KR20047010847A KR100964604B1 KR 100964604 B1 KR100964604 B1 KR 100964604B1 KR 1020047010847 A KR1020047010847 A KR 1020047010847A KR 20047010847 A KR20047010847 A KR 20047010847A KR 100964604 B1 KR100964604 B1 KR 100964604B1
- Authority
- KR
- South Korea
- Prior art keywords
- hemoglobin
- oxygen
- blood
- artificial blood
- modified
- Prior art date
Links
- 108010054147 Hemoglobins Proteins 0.000 title claims abstract description 243
- 102000001554 Hemoglobins Human genes 0.000 title claims abstract description 243
- 239000000203 mixture Substances 0.000 title claims abstract description 33
- 238000000034 method Methods 0.000 title claims description 44
- 229910052760 oxygen Inorganic materials 0.000 title abstract description 136
- 239000001301 oxygen Substances 0.000 title abstract description 136
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 title abstract description 134
- 229940125691 blood product Drugs 0.000 claims abstract description 10
- 238000004519 manufacturing process Methods 0.000 claims abstract description 9
- 239000008280 blood Substances 0.000 claims description 73
- 210000004369 blood Anatomy 0.000 claims description 72
- 239000002473 artificial blood Substances 0.000 claims description 70
- 241001465754 Metazoa Species 0.000 claims description 53
- 229920001223 polyethylene glycol Polymers 0.000 claims description 34
- 239000002202 Polyethylene glycol Substances 0.000 claims description 21
- 241000282414 Homo sapiens Species 0.000 claims description 16
- 108010061951 Methemoglobin Proteins 0.000 claims description 15
- 239000003795 chemical substances by application Substances 0.000 claims description 14
- 229920000642 polymer Polymers 0.000 claims description 14
- 238000012986 modification Methods 0.000 claims description 13
- 230000004048 modification Effects 0.000 claims description 12
- 239000003085 diluting agent Substances 0.000 claims description 11
- 241000283073 Equus caballus Species 0.000 claims description 10
- 208000007502 anemia Diseases 0.000 claims description 10
- 125000003396 thiol group Chemical group [H]S* 0.000 claims description 10
- 108010031004 PEG-hemoglobin Proteins 0.000 claims description 9
- 206010028980 Neoplasm Diseases 0.000 claims description 7
- 108010001708 stroma free hemoglobin Proteins 0.000 claims description 6
- 230000002949 hemolytic effect Effects 0.000 claims description 5
- 208000014674 injury Diseases 0.000 claims description 5
- -1 succinimidyl Chemical group 0.000 claims description 5
- 208000032467 Aplastic anaemia Diseases 0.000 claims description 4
- 206010021143 Hypoxia Diseases 0.000 claims description 4
- 125000000217 alkyl group Chemical group 0.000 claims description 4
- 208000007475 hemolytic anemia Diseases 0.000 claims description 4
- 206010041660 Splenomegaly Diseases 0.000 claims description 3
- 201000011510 cancer Diseases 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 208000015181 infectious disease Diseases 0.000 claims description 3
- 230000002458 infectious effect Effects 0.000 claims description 3
- 208000007056 sickle cell anemia Diseases 0.000 claims description 3
- 230000008733 trauma Effects 0.000 claims description 3
- 208000035143 Bacterial infection Diseases 0.000 claims description 2
- 241000282324 Felis Species 0.000 claims description 2
- 206010021074 Hypoplastic anaemia Diseases 0.000 claims description 2
- 206010022971 Iron Deficiencies Diseases 0.000 claims description 2
- 206010040070 Septic Shock Diseases 0.000 claims description 2
- 208000027418 Wounds and injury Diseases 0.000 claims description 2
- 208000022362 bacterial infectious disease Diseases 0.000 claims description 2
- 230000006378 damage Effects 0.000 claims description 2
- 238000013467 fragmentation Methods 0.000 claims description 2
- 238000006062 fragmentation reaction Methods 0.000 claims description 2
- 230000002008 hemorrhagic effect Effects 0.000 claims description 2
- 230000007954 hypoxia Effects 0.000 claims description 2
- 208000028867 ischemia Diseases 0.000 claims description 2
- 230000024241 parasitism Effects 0.000 claims description 2
- 244000144977 poultry Species 0.000 claims description 2
- 230000036303 septic shock Effects 0.000 claims description 2
- 208000011580 syndromic disease Diseases 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 238000007254 oxidation reaction Methods 0.000 abstract description 15
- 230000003647 oxidation Effects 0.000 abstract description 12
- 239000010836 blood and blood product Substances 0.000 abstract description 7
- 230000001976 improved effect Effects 0.000 abstract description 3
- 239000000243 solution Substances 0.000 description 41
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 34
- 210000003743 erythrocyte Anatomy 0.000 description 30
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 24
- 210000001519 tissue Anatomy 0.000 description 24
- 239000000306 component Substances 0.000 description 22
- 208000032843 Hemorrhage Diseases 0.000 description 20
- 230000000740 bleeding effect Effects 0.000 description 17
- 238000006243 chemical reaction Methods 0.000 description 13
- 230000001965 increasing effect Effects 0.000 description 13
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 11
- 230000027455 binding Effects 0.000 description 11
- 230000036772 blood pressure Effects 0.000 description 11
- 239000008156 Ringer's lactate solution Substances 0.000 description 10
- ZEWYCNBZMPELPF-UHFFFAOYSA-J calcium;potassium;sodium;2-hydroxypropanoic acid;sodium;tetrachloride Chemical compound [Na].[Na+].[Cl-].[Cl-].[Cl-].[Cl-].[K+].[Ca+2].CC(O)C(O)=O ZEWYCNBZMPELPF-UHFFFAOYSA-J 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- 238000004458 analytical method Methods 0.000 description 9
- 239000003633 blood substitute Substances 0.000 description 9
- 238000002146 exchange transfusion Methods 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 9
- 235000018102 proteins Nutrition 0.000 description 9
- 108090000623 proteins and genes Proteins 0.000 description 9
- 102000004169 proteins and genes Human genes 0.000 description 9
- 239000000126 substance Substances 0.000 description 9
- 238000009792 diffusion process Methods 0.000 description 8
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 8
- 239000012528 membrane Substances 0.000 description 8
- 210000000056 organ Anatomy 0.000 description 8
- 230000003204 osmotic effect Effects 0.000 description 8
- 239000002953 phosphate buffered saline Substances 0.000 description 8
- 206010047139 Vasoconstriction Diseases 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 7
- 239000000084 colloidal system Substances 0.000 description 7
- 238000005259 measurement Methods 0.000 description 7
- 229920000233 poly(alkylene oxides) Polymers 0.000 description 7
- 230000002829 reductive effect Effects 0.000 description 7
- 230000002792 vascular Effects 0.000 description 7
- 230000025033 vasoconstriction Effects 0.000 description 7
- 206010020772 Hypertension Diseases 0.000 description 6
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 6
- 230000004872 arterial blood pressure Effects 0.000 description 6
- 239000000969 carrier Substances 0.000 description 6
- 230000021615 conjugation Effects 0.000 description 6
- NGVDGCNFYWLIFO-UHFFFAOYSA-N pyridoxal 5'-phosphate Chemical compound CC1=NC=C(COP(O)(O)=O)C(C=O)=C1O NGVDGCNFYWLIFO-UHFFFAOYSA-N 0.000 description 6
- 229960001327 pyridoxal phosphate Drugs 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- 238000003860 storage Methods 0.000 description 6
- 238000001356 surgical procedure Methods 0.000 description 6
- 229920002307 Dextran Polymers 0.000 description 5
- 239000007864 aqueous solution Substances 0.000 description 5
- 210000001367 artery Anatomy 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 125000003636 chemical group Chemical group 0.000 description 5
- 239000003638 chemical reducing agent Substances 0.000 description 5
- 238000001802 infusion Methods 0.000 description 5
- 210000000265 leukocyte Anatomy 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 235000007682 pyridoxal 5'-phosphate Nutrition 0.000 description 5
- 239000011589 pyridoxal 5'-phosphate Substances 0.000 description 5
- 238000011084 recovery Methods 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- CYWHLOXWVAWMFO-UHFFFAOYSA-N 3-sulfanyl-1h-pyridine-2-thione Chemical compound SC1=CC=CN=C1S CYWHLOXWVAWMFO-UHFFFAOYSA-N 0.000 description 4
- 239000004606 Fillers/Extenders Substances 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 230000017531 blood circulation Effects 0.000 description 4
- 238000004132 cross linking Methods 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 239000007789 gas Substances 0.000 description 4
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 4
- 150000003278 haem Chemical class 0.000 description 4
- 238000005534 hematocrit Methods 0.000 description 4
- 239000004310 lactic acid Substances 0.000 description 4
- 235000014655 lactic acid Nutrition 0.000 description 4
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 4
- 230000010412 perfusion Effects 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 238000005057 refrigeration Methods 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 238000006177 thiolation reaction Methods 0.000 description 4
- INGWEZCOABYORO-UHFFFAOYSA-N 2-(furan-2-yl)-7-methyl-1h-1,8-naphthyridin-4-one Chemical class N=1C2=NC(C)=CC=C2C(O)=CC=1C1=CC=CO1 INGWEZCOABYORO-UHFFFAOYSA-N 0.000 description 3
- 102000009027 Albumins Human genes 0.000 description 3
- 108010088751 Albumins Proteins 0.000 description 3
- 241000283690 Bos taurus Species 0.000 description 3
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 3
- 206010061216 Infarction Diseases 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 239000012298 atmosphere Substances 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 230000004087 circulation Effects 0.000 description 3
- 230000002016 colloidosmotic effect Effects 0.000 description 3
- 230000008602 contraction Effects 0.000 description 3
- 230000035487 diastolic blood pressure Effects 0.000 description 3
- 229910001882 dioxygen Inorganic materials 0.000 description 3
- 230000003511 endothelial effect Effects 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 102000018146 globin Human genes 0.000 description 3
- 108060003196 globin Proteins 0.000 description 3
- 230000000004 hemodynamic effect Effects 0.000 description 3
- 108010036302 hemoglobin AS Proteins 0.000 description 3
- 230000001146 hypoxic effect Effects 0.000 description 3
- 230000007574 infarction Effects 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 239000002502 liposome Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000004811 liquid chromatography Methods 0.000 description 3
- 239000006166 lysate Substances 0.000 description 3
- 230000014759 maintenance of location Effects 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 230000036961 partial effect Effects 0.000 description 3
- 230000006320 pegylation Effects 0.000 description 3
- 230000035939 shock Effects 0.000 description 3
- 238000004659 sterilization and disinfection Methods 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 229920001059 synthetic polymer Polymers 0.000 description 3
- 239000012085 test solution Substances 0.000 description 3
- 150000003573 thiols Chemical class 0.000 description 3
- HCXJFMDOHDNDCC-UHFFFAOYSA-N 5-$l^{1}-oxidanyl-3,4-dihydropyrrol-2-one Chemical group O=C1CCC(=O)[N]1 HCXJFMDOHDNDCC-UHFFFAOYSA-N 0.000 description 2
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical group NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 241000283086 Equidae Species 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 108010024636 Glutathione Proteins 0.000 description 2
- 108091005904 Hemoglobin subunit beta Proteins 0.000 description 2
- 208000032456 Hemorrhagic Shock Diseases 0.000 description 2
- 238000010824 Kaplan-Meier survival analysis Methods 0.000 description 2
- 206010070834 Sensitisation Diseases 0.000 description 2
- 206010040047 Sepsis Diseases 0.000 description 2
- 206010049771 Shock haemorrhagic Diseases 0.000 description 2
- 241000282887 Suidae Species 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 230000000735 allogeneic effect Effects 0.000 description 2
- 150000001408 amides Chemical group 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 230000036760 body temperature Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 230000000747 cardiac effect Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000007385 chemical modification Methods 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- 238000007398 colorimetric assay Methods 0.000 description 2
- 238000005138 cryopreservation Methods 0.000 description 2
- 230000009089 cytolysis Effects 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 238000004925 denaturation Methods 0.000 description 2
- 230000036425 denaturation Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 239000002158 endotoxin Substances 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 229960003180 glutathione Drugs 0.000 description 2
- 230000002489 hematologic effect Effects 0.000 description 2
- 230000001631 hypertensive effect Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 125000005647 linker group Chemical group 0.000 description 2
- 231100000053 low toxicity Toxicity 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000004089 microcirculation Effects 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 125000006353 oxyethylene group Chemical group 0.000 description 2
- 230000036284 oxygen consumption Effects 0.000 description 2
- 238000006213 oxygenation reaction Methods 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 230000001766 physiological effect Effects 0.000 description 2
- 230000035790 physiological processes and functions Effects 0.000 description 2
- 238000006116 polymerization reaction Methods 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 239000002510 pyrogen Substances 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 238000010188 recombinant method Methods 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000008313 sensitization Effects 0.000 description 2
- 238000001542 size-exclusion chromatography Methods 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 230000035488 systolic blood pressure Effects 0.000 description 2
- TXEYQDLBPFQVAA-UHFFFAOYSA-N tetrafluoromethane Chemical compound FC(F)(F)F TXEYQDLBPFQVAA-UHFFFAOYSA-N 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- CNHYKKNIIGEXAY-UHFFFAOYSA-N thiolan-2-imine Chemical compound N=C1CCCS1 CNHYKKNIIGEXAY-UHFFFAOYSA-N 0.000 description 2
- NGCGPAYNMSJQCY-UHFFFAOYSA-N thiophen-3-imine Chemical compound N=C1CSC=C1 NGCGPAYNMSJQCY-UHFFFAOYSA-N 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 210000003437 trachea Anatomy 0.000 description 2
- 238000000108 ultra-filtration Methods 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 239000002699 waste material Substances 0.000 description 2
- 241000271566 Aves Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 208000010248 Cerebrovascular Trauma Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 241000938605 Crocodylia Species 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- CWYNVVGOOAEACU-UHFFFAOYSA-N Fe2+ Chemical compound [Fe+2] CWYNVVGOOAEACU-UHFFFAOYSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 206010059484 Haemodilution Diseases 0.000 description 1
- 102000008015 Hemeproteins Human genes 0.000 description 1
- 108010089792 Hemeproteins Proteins 0.000 description 1
- 102100021519 Hemoglobin subunit beta Human genes 0.000 description 1
- 101001009007 Homo sapiens Hemoglobin subunit alpha Proteins 0.000 description 1
- 229920001612 Hydroxyethyl starch Polymers 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 108010064719 Oxyhemoglobins Proteins 0.000 description 1
- 229920002123 Pentastarch Polymers 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 229920000604 Polyethylene Glycol 200 Polymers 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 150000001413 amino acids Chemical group 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 210000002565 arteriole Anatomy 0.000 description 1
- 230000001746 atrial effect Effects 0.000 description 1
- 230000010455 autoregulation Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 238000009530 blood pressure measurement Methods 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 238000013130 cardiovascular surgery Methods 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000006392 deoxygenation reaction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 108010074807 diaspirin-cross-linked hemoglobin Proteins 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- REQPQFUJGGOFQL-UHFFFAOYSA-N dimethylcarbamothioyl n,n-dimethylcarbamodithioate Chemical compound CN(C)C(=S)SC(=S)N(C)C REQPQFUJGGOFQL-UHFFFAOYSA-N 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000008344 egg yolk phospholipid Substances 0.000 description 1
- 229940068998 egg yolk phospholipid Drugs 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 208000009724 equine infectious anemia Diseases 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 210000001105 femoral artery Anatomy 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 239000000446 fuel Substances 0.000 description 1
- 238000004868 gas analysis Methods 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 125000003827 glycol group Chemical group 0.000 description 1
- 244000144993 groups of animals Species 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 238000011553 hamster model Methods 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 229920001477 hydrophilic polymer Polymers 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 210000003093 intracellular space Anatomy 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- YWXYYJSYQOXTPL-SLPGGIOYSA-N isosorbide mononitrate Chemical compound [O-][N+](=O)O[C@@H]1CO[C@@H]2[C@@H](O)CO[C@@H]21 YWXYYJSYQOXTPL-SLPGGIOYSA-N 0.000 description 1
- 150000002605 large molecules Chemical class 0.000 description 1
- 210000005240 left ventricle Anatomy 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 238000005374 membrane filtration Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 210000004088 microvessel Anatomy 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 238000011330 nucleic acid test Methods 0.000 description 1
- 238000006384 oligomerization reaction Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 238000012261 overproduction Methods 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 238000002496 oximetry Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000002572 peristaltic effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000009520 phase I clinical trial Methods 0.000 description 1
- 238000009522 phase III clinical trial Methods 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000003058 plasma substitute Substances 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 238000011176 pooling Methods 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000002315 pressor effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 208000002815 pulmonary hypertension Diseases 0.000 description 1
- 230000035485 pulse pressure Effects 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 210000005245 right atrium Anatomy 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 238000013222 sprague-dawley male rat Methods 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 208000037905 systemic hypertension Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 230000019432 tissue death Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 208000010926 vascular brain injury Diseases 0.000 description 1
- 230000006442 vascular tone Effects 0.000 description 1
- 239000005526 vasoconstrictor agent Substances 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/41—Porphyrin- or corrin-ring-containing peptides
- A61K38/42—Haemoglobins; Myoglobins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Zoology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Food Preservation Except Freezing, Refrigeration, And Drying (AREA)
- Solid-Sorbent Or Filter-Aiding Compositions (AREA)
Abstract
Description
조혈(Hematopoiesis). 인공혈액은 조혈과정 동안 새로운 헤모글로빈을 합성하는데 사용되는 헴과 철의 기원으로서 제공될 수 있다.
테스트 | 세부 사항 |
헤모글로빈 농도(g/dl) | 4.2±0.2 |
메트헤모글로빈(%) | <10 |
pH | 7.4±0.4 |
전도율(mS/cm) | 12±4 |
내독소(EU/mL) | <0.5 |
FPLC 머무름 시간(분) | 43±3 |
절반 높이에서 FPLC 피크 넓이(분) | 6±2 |
점도(cPs) | 2.5±1.0 |
COP(mmHg) | 50±20 |
P50(torr) | 6±2 |
힐 넘버(Hill number, P50에서) | 1.2±0.5 |
무균상태 | 통과 |
혈액 | SFH | MalPEG-Hb | |
P50 (torr) | 28 | 15 | 5 |
N50 (힐 넘버) | 2.9 | 2.9 | 1.2 |
보어 효과(ΔLog P50/ΔpH) | -- | -0.46 | -0.20 |
점도(cPs)1 | 4.0 | 0.9 | 2.5 |
COP(mm Hg)1 | 27 | 16 | 50 |
MW (kD)2 | N/A | 65 | 90 |
분자 반경(nm) | 4000 | 3.22 | 9 |
PHP | POE | |
Hb, g/dl | 8.0 | 8.3 |
점도 (cP) | 2.8 | 2.8 |
COP, mm Hg | 62.7 | 56.5 |
*a1(×10-1) | 1.368 | 2.228 |
*a2(×10-3) | 9.680 | 21.070 |
*a3(×10-5) | 0.752 | 46.500 |
*a4(×10-5) | 1.537 | 8.766 |
P50 | 19.7 | 12.2 |
n50 | 1.48 | 1.49 |
WT(g) | *혈액부피(ml) | 출혈부피(ml) | 출혈부피(%) | 사망시간(분) | ||
PHP | n | 18 | 18 | 18 | 18 | 18 |
PHP | 291 | 18.89 | 11.10 | 58.79 | 93 | |
sd | 24 | 1.59 | 0.90 | 0.35 | 29 | |
POE | n | 11 | 11 | 11 | 11 | 11 |
POE | 334 | 21.74 | 12.78 | 58.77 | 116 | |
sd | 41 | 2.65 | 1.60 | 0.39 | 12 | |
P | 0.001 | 0.001 | 0.001 | 0.915 | 0.020 |
n | PHP | sem | n | POE | sem | P | ||
HCT | 기준선 | 17 | 39.80 | 0.57 | 10 | 43.15 | 0.23 | 0.0032 |
ET 후 | 17 | 17.89 | 0.43 | 10 | 19.25 | 0.62 | 0.3568 | |
60분 | 15 | 13.29 | 0.47 | 10 | 15.85 | 0.14 | 0.0015 | |
HB | 기준선 | 17 | 13.59 | 0.22 | 10 | 15.08 | 0.17 | 0.0057 |
ET 후 | 17 | 8.70 | 0.18 | 10 | 9.74 | 0.07 | 0.0007 | |
60분 | 15 | 6.34 | 0.21 | 10 | 7.38 | 0.06 | 0.0016 | |
PLHB | 기준선 | 16 | 0.00 | 0.00 | 10 | 0.00 | 0.00 | |
ET 후 | 16 | 2.86 | 0.07 | 10 | 2.99 | 0.09 | 0.6785 | |
60분 | 15 | 1.93 | 0.07 | 10 | 2.47 | 0.02 | 0.0001 | |
LACT | 기준선 | 9 | 0.70 | 0.06 | 7 | 2.68 | 0.16 | 0.0001 |
ET 후 | 9 | 1.59 | 0.10 | 7 | 4.21 | 0.24 | 0.0004 | |
60분 | 9 | 10.62 | 0.89 | 7 | 17.27 | 1.18 | 0.0360 | |
BE | 기준선 | 17 | 6.22 | 1.28 | 9 | 5.41 | 0.08 | 0.6530 |
ET 후 | 17 | 6.20 | 1.41 | 5 | 5.60 | 0.13 | 0.8101 | |
60분 | 15 | -4.02 | 1.60 | 6 | -1.60 | 0.53 | 0.4678 |
Claims (19)
- 표면-개질된 산화 헤모글로빈을 포함하고,상기 표면-개질된 산화 헤모글로빈은 헤모글로빈이 산화된 상태에 있는 동안 헤모글로빈 분자 표면에 노출된 아미노산 측쇄(side-chain)의 표면 티올기(thiol group)를 통하여 폴리에틸렌 글리콜이 공유결합으로 부착되어 있는 헤모글로빈이고,상기 폴리에틸렌 글리콜은 알킬기를 통해 결합되고,상기 표면-개질된 산화 헤모글로빈은 동일한 조건하에서 측정하였을 때 동일한 동물 소스(source) 유래의 천연 무지질(stroma-free) 헤모글로빈의 P50의 2/3이하의 P50을 갖는 것을 특징으로 하는 인공 혈액제.
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 제1항에 있어서,표면-개질된 산화 헤모글로빈을 포함하고,상기 표면-개질된 산화 헤모글로빈은 하기 일반식을 갖고:Hb-(S-Y-R-CH2-CH2-[O-CH2-CH2]n-O-CH3)m상기 식에서,Hb는 사량체(tetrameric) 헤모글로빈이고;S는 표면 티올기(thiol group)이고;Y는 숙신이미딜(succinimidyl) 공유 결합(covalent link)이고;R은 알킬기(alkyl group)이고;n은 중합체(polymer)의 길이를 의미하는 것이며, 4 이상이고;m은 헤모글로빈의 표면에 부착된 PEG 중합체의 개수이고;상기 표면-개질된 산화 헤모글로빈은 동일한 조건하에서 측정하였을 때 동일한 동물 소스(source) 유래의 천연 무지질(stroma-free) 헤모글로빈의 P50의 2/3이하의 P50을 갖는 것을 특징으로 하는 인공 혈액제.
- 제7항에 있어서,상기 m은 4 내지 5인 것을 특징으로 하는 인공 혈액제.
- 제1항 또는 제7항에 있어서,상기 표면 개질 이전에 상기 헤모글로빈이 티올화(thiolated) 된 것을 특징으로 하는 인공 혈액제.
- 제1항 또는 제7항에 있어서,0.10 미만의 메트헤모글로빈(methemoglobin)/총 헤모글로빈의 비를 갖는 것을 특징으로 하는 인공 혈액제.
- 제1항 또는 제7항에 있어서,상기 표면 개질된 산화 헤모글로빈은 10 토르(torr)(1333 Pa) 미만의 P50을 갖는 것을 특징으로 하는 인공 혈액제.
- 제1항 또는 제7항에 있어서,상기 표면 개질된 산화 헤모글로빈은 7 토르(torr)(933 Pa) 미만의 P50을 갖는 것을 특징으로 하는 인공 혈액제.
- 제1항 또는 제7항에 있어서,PEG-헤모글로빈 접합체(conjugate)를 포함하여 24℃에서 자동산화(autooxidation)에 대해 안정하고, 상기 메트헤모글로빈/총 헤모글로빈의 비는 0.10 미만이고, 상기 PEG-헤모글로빈 접합체(conjugate)는 10 토르(torr)(1333 Pa) 미만의 P50을 갖는 것을 특징으로 하는 인공 혈액제.
- 제1항에 있어서,상기 헤모글로빈은 말(horse) 헤모글로빈인 것을 특징으로 하는 인공 혈액제.
- 수용성 희석제(aqueous diluent) 중에 제1항 또는 제7항에 따른 인공 혈액제를 포함하는 인공 혈액용 조성물.
- 제15항에 있어서,상기 헤모글로빈의 농도는 0.1 내지 4.0 g/㎗인 것을 특징으로 하는 인공 혈액용 조성물.
- 제1항 또는 제7항에 있어서,인간 또는 동물체의 치료 방법에 유용한 것을 특징으로 하는 인공 혈액제.
- 제1항에 있어서,상기 인공 혈액제는 외상(trauma), 빈혈(ischemia), 혈액희석(hemodilution), 패혈증 쇼크(septic shock), 암(cancer), 만성빈혈증(chronic anemia), 겸상 적혈구 빈혈증(sickle-cell anemia), 심장마비(cardioplegia) 또는 저산소증(hypoxia)의 치료를 위한 약제 제조에 사용되는 것을 특징으로 하는 인공 혈액제.
- 제1항에 있어서,상기 인공 혈액제는 상해로 인한 혈액손실(loss of blood due to injury), 용혈성 빈혈증(haemolytic anemia), 전염성 빈혈증(equine infectious anemia), 고양이 전염성 빈혈증(feline infectious anemia), 박테리아 감염(bacterial infection), 인자 IV 분열(factor IV fragmentation), 비대증(hypersplenation)과 비종대(splenomegaly), 가금류에서의 출혈증후군(hemorrhagic syndrome in poultry), 발육부전성 빈혈(hypoplastic anemia), 재생불량성 빈혈(aplastic anemia), 본태성 면역 용혈 상태(idiopathic immune haemolytic condition), 철 결핍(iron deficiency), 동족면역 용혈성 빈혈(isoimmune haemolytic anemia), 미세혈관성 용혈성 빈혈(microangiopahtic haemolytic anemia) 또는 기생(parasitism)의 수의학적 치료를 위한 약제 제조에 사용되는 것을 특징으로 하는 인공 혈액제.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US34774102P | 2002-01-11 | 2002-01-11 | |
US60/347,741 | 2002-01-11 | ||
US10/114,400 US20030153491A1 (en) | 2002-01-11 | 2002-04-01 | Methods and compositions for oxygen transport comprising a high oxygen affinity modified hemoglobin |
US10/114,400 | 2002-04-01 | ||
PCT/US2003/000696 WO2003059363A1 (en) | 2002-01-11 | 2003-01-10 | Methods and compositions for oxygen transport comprising a high oyzgen affinity |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20040081451A KR20040081451A (ko) | 2004-09-21 |
KR100964604B1 true KR100964604B1 (ko) | 2010-06-21 |
Family
ID=26812138
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020047010847A KR100964604B1 (ko) | 2002-01-11 | 2003-01-10 | 산소 친화도가 높은 개질된 헤모글로빈을 포함하는 산소 전달용 조성물 및 방법 |
Country Status (15)
Country | Link |
---|---|
US (3) | US20030153491A1 (ko) |
EP (1) | EP1465643B1 (ko) |
JP (2) | JP5149480B2 (ko) |
KR (1) | KR100964604B1 (ko) |
CN (2) | CN1630527B (ko) |
AT (1) | ATE382358T1 (ko) |
AU (1) | AU2003207504B2 (ko) |
BR (1) | BR0306846A (ko) |
CA (1) | CA2473662C (ko) |
DE (1) | DE60318388T2 (ko) |
DK (1) | DK1465643T3 (ko) |
ES (1) | ES2299686T3 (ko) |
MX (1) | MXPA04006733A (ko) |
PT (1) | PT1465643E (ko) |
WO (1) | WO2003059363A1 (ko) |
Families Citing this family (51)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6602498B2 (en) | 2000-02-22 | 2003-08-05 | Shearwater Corporation | N-maleimidyl polymer derivatives |
US20050164915A1 (en) * | 2002-04-01 | 2005-07-28 | Sangart, Inc. | Compositions for oxygen transport comprising a high oxygen affinity modified hemoglobin |
US7501499B2 (en) * | 2002-12-23 | 2009-03-10 | Albert Einstein College Of Medicine Of Yeshiva University | Modified hemoglobin and methods of making same |
US7432331B2 (en) | 2002-12-31 | 2008-10-07 | Nektar Therapeutics Al, Corporation | Hydrolytically stable maleimide-terminated polymers |
JP4490290B2 (ja) * | 2002-12-31 | 2010-06-23 | ネクター セラピューティクス アラバマ,コーポレイション | 加水分解安定性マレイミド末端ポリマー |
AU2004297228A1 (en) | 2003-12-03 | 2005-06-23 | Nektar Therapeutics Al, Corporation | Method of preparing maleimide functionalized polymers |
JP2008511674A (ja) * | 2004-08-31 | 2008-04-17 | サンガート, インコーポレイテッド | 酸素運搬成分を使用して血流力学的安定性を増強する方法 |
US8455437B2 (en) * | 2005-02-04 | 2013-06-04 | The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | Method to predict and prevent oxygen-induced inflammatory tissue injury |
EP1863503B1 (en) * | 2005-03-07 | 2019-05-22 | Sangart, Inc. | Composition for delivering carbon monoxide (co) and nitric ozide (no) co to tissue using heme proteins as carriers |
WO2007050121A2 (en) * | 2005-05-11 | 2007-05-03 | Albert Einstein College Of Medicine Of Yeshiva University | Site specific pegylated hemoglobin, method of preparing same, and uses thereof |
WO2007058678A2 (en) * | 2005-06-10 | 2007-05-24 | Albert Einstein College Of Medicine Of Yeshiva University | Uses of pegylated albumin |
US8741832B2 (en) * | 2005-06-10 | 2014-06-03 | Albert Einstein College Of Medicine Of Yeshiva University | Pegylated albumin and uses thereof |
DE602006013151D1 (de) | 2005-07-19 | 2010-05-06 | Nektar Therapeutics | Verfahren zur herstellung von polymermaleimiden |
DK2040740T3 (en) | 2006-05-22 | 2014-12-01 | Univ California | COMPOSITIONS AND PROCEDURES FOR DELIVERING NITROGEN MONOXIDE |
US7504377B2 (en) * | 2006-10-23 | 2009-03-17 | Ikor, Inc. | Nitric oxide-blocked cross-linked tetrameric hemoglobin |
CN101158676B (zh) * | 2006-12-31 | 2011-12-14 | 重庆大学 | 一种评价血液及其代用品携氧、释氧功能的分析方法及装置 |
US20090191244A1 (en) * | 2007-09-27 | 2009-07-30 | Children's Medical Center Corporation | Microbubbles and methods for oxygen delivery |
US10172949B2 (en) | 2009-06-09 | 2019-01-08 | Prolong Pharmaceuticals, LLC | Hemoglobin compositions |
US10172950B2 (en) | 2009-06-09 | 2019-01-08 | Prolong Pharmaceuticals, LLC | Hemoglobin compositions |
TWI626057B (zh) | 2009-06-09 | 2018-06-11 | 普龍製藥有限責任公司 | 血紅素組成物 |
US9114109B2 (en) * | 2009-06-16 | 2015-08-25 | University of Pittsburgh—of the Commonwealth System of Higher Education | Five-coordinate neuroglobin and use thereof as a blood substitute |
US8273857B2 (en) * | 2009-09-22 | 2012-09-25 | Jen-Chang Hsia | Compositions and methods of use of neurovascular protective multifunctional polynitroxylated pegylated carboxy hemoglobins for transfusion and critical care medicine |
WO2011056799A1 (en) * | 2009-11-05 | 2011-05-12 | Sangart, Inc. | Methods for preparing polyethylene glycol maleimide using n-(2-hydroxyethyl) maleimide as a starting material |
AU2011220885A1 (en) * | 2010-02-25 | 2012-09-06 | Sangart, Inc. | Methods for preparing PEG-hemoglobin conjugates using reduced reactant ratios |
US7989593B1 (en) | 2010-05-27 | 2011-08-02 | Bing Lou Wong | Method for the preparation of a high-temperature stable oxygen-carrier-containing pharmaceutical composition and the use thereof |
US8048856B1 (en) | 2010-06-23 | 2011-11-01 | Billion King, Ltd. | Treatment methods using a heat stable oxygen carrier-containing pharmaceutical composition |
US7932356B1 (en) | 2010-06-23 | 2011-04-26 | Bing Lou Wong | Method for the preparation of a heat stable oxygen carrier-containing pharmaceutical composition |
DK2661275T3 (en) * | 2011-01-07 | 2019-04-15 | Poseida Therapeutics Inc | COMPOSITIONS AND METHODS FOR ADMINISTRATING THE HIGH OXYGEN EFFICIENCY TO TUMORS FOR THE ADMINISTRATION |
US20120196270A1 (en) * | 2011-02-02 | 2012-08-02 | Sangart, Inc. | Methods for preserving an organ for transplantation using a hemoglobin-carbon monoxide complex |
US8889830B2 (en) | 2011-03-01 | 2014-11-18 | Chuo University | Hemoglobin-albumin complex, and artificial plasma expander and artificial oxygen carrier containing the complex |
US8084581B1 (en) | 2011-04-29 | 2011-12-27 | Bing Lou Wong | Method for removing unmodified hemoglobin from cross-linked hemoglobin solutions including polymeric hemoglobin with a high temperature short time heat treatment apparatus |
US20130052232A1 (en) | 2011-08-31 | 2013-02-28 | Bing Lou Wong | Method for the preparation of a heat stable oxygen carrier-containing composition facilating beta-beta cross-linking |
JP6389125B2 (ja) * | 2011-11-07 | 2018-09-12 | ザ ジェネラル ホスピタル コーポレイション | 赤血球の処理法 |
MX358785B (es) * | 2012-03-29 | 2018-09-04 | Sangart Inc | Hemoglobina pegilada reticulada con diaspirina. |
KR102076874B1 (ko) | 2012-04-03 | 2020-02-12 | 쉰들러, 윌리엄 | 숙신이미드-활성화 나이트록실 화합물 및 단백질의 나이트록실화를 위한 이의 사용 방법 |
WO2013151682A1 (en) | 2012-04-06 | 2013-10-10 | Children's Medical Center Corporation | Process for forming microbubbles with high oxygen content and uses thereof |
US10385116B2 (en) | 2013-01-07 | 2019-08-20 | Omniox, Inc. | Polymeric forms of H-NOX proteins |
WO2014144364A1 (en) | 2013-03-15 | 2014-09-18 | Children's Medical Center Corporation | Gas-filled stabilized particles and methods of use |
KR102238718B1 (ko) | 2013-03-15 | 2021-04-12 | 쉰들러, 윌리엄 | 폴리알킬렌 산화물 발레르산염 헤모글로빈 접합체 |
US10456452B2 (en) | 2015-07-02 | 2019-10-29 | Poseida Therapeutics, Inc. | Compositions and methods for improved encapsulation of functional proteins in polymeric vesicles |
CN105497894B (zh) * | 2015-12-21 | 2019-01-04 | 中国科学院深圳先进技术研究院 | 用于肿瘤光动力治疗的血红蛋白-光敏剂试剂及其应用 |
ES2939181T3 (es) | 2016-02-16 | 2023-04-19 | Omniox Inc | Modulación de hipoxia asociada con accidente cerebrovascular |
EP3449004B1 (en) | 2016-04-29 | 2021-02-24 | Poseida Therapeutics, Inc. | Poly(histidine)-based micelles for complexation and delivery of proteins and nucleic acids |
WO2018008729A1 (ja) | 2016-07-06 | 2018-01-11 | 学校法人 中央大学 | 虚血性疾患の治療剤 |
ES2651717B1 (es) * | 2016-07-26 | 2018-11-16 | Lara OLLER DUQUE | Solución acuosa cristaloide isotónica |
US11147890B2 (en) | 2017-02-28 | 2021-10-19 | Children's Medical Center Corporation | Stimuli-responsive particles encapsulating a gas and methods of use |
AU2019264885A1 (en) * | 2018-05-11 | 2020-11-26 | Spectronix Inc. | Abnormal blood oxygenation level monitoring system and method, and self-monitoring oxygenation system and method |
EP3836911A1 (en) | 2018-08-15 | 2021-06-23 | Omniox, Inc. | H-nox proteins for treating cardiovascular and pulmonary conditions |
CN111499732B (zh) * | 2020-04-22 | 2022-05-13 | 中国科学院过程工程研究所 | 一种基于双重化学修饰的血红蛋白氧载体及其制备方法和应用 |
WO2021261712A1 (en) * | 2020-06-26 | 2021-12-30 | Sunbio, Inc. | Hemoglobin derivative co-conjugated with fatty acid-linked peg and alkoxy peg as a blood substitute |
CN114617957B (zh) * | 2022-03-10 | 2024-01-16 | 中国人民解放军军事科学院军事医学研究院 | 羟乙基淀粉血红蛋白偶联物及其制备方法与应用 |
Family Cites Families (99)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3507146A (en) | 1968-02-09 | 1970-04-21 | Webb James E | Method and system for respiration analysis |
US3956259A (en) | 1973-01-30 | 1976-05-11 | Baxter Laboratories, Inc. | Fractionation of blood using block copolymer of ethylene oxide and polyoxypropylene polymer to recover fraction suitable for organ perfusate |
US3925344A (en) * | 1973-04-11 | 1975-12-09 | Community Blood Council | Plasma protein substitute |
US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
DE2449885C3 (de) | 1974-10-21 | 1980-04-30 | Biotest-Serum-Institut Gmbh, 6000 Frankfurt | Verfahren zur Herstellung von chemisch modifizierten haltbaren Hämoglobinpräparaten sowie das nach diesem Verfahren hergestellte modifizierte Hämoglobinpräparat |
US4001401A (en) * | 1975-02-02 | 1977-01-04 | Alza Corporation | Blood substitute and blood plasma expander comprising polyhemoglobin |
US4001200A (en) | 1975-02-27 | 1977-01-04 | Alza Corporation | Novel polymerized, cross-linked, stromal-free hemoglobin |
US4061736A (en) * | 1975-02-02 | 1977-12-06 | Alza Corporation | Pharmaceutically acceptable intramolecularly cross-linked, stromal-free hemoglobin |
US4053590A (en) | 1975-02-27 | 1977-10-11 | Alza Corporation | Compositions of matter comprising macromolecular hemoglobin |
CA1055932A (en) | 1975-10-22 | 1979-06-05 | Hematech Inc. | Blood substitute based on hemoglobin |
GB1578776A (en) | 1976-06-10 | 1980-11-12 | Univ Illinois | Hemoglobin liposome and method of making the same |
JPS5329908A (en) | 1976-08-27 | 1978-03-20 | Green Cross Corp:The | Immobilized haptoglobin preparation |
US4209300A (en) | 1978-09-25 | 1980-06-24 | The United States Of America As Represented By The Department Of Health, Education And Welfare | Hemoglobin-oxygen equilibrium curve analyzer |
JPS6023084B2 (ja) * | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
JPS5716815A (en) | 1980-07-02 | 1982-01-28 | Ajinomoto Co Inc | Oxygen transporting agent for artificial blood |
US4401652A (en) | 1980-12-31 | 1983-08-30 | Allied Corporation | Process for the preparation of stroma-free hemoglobin solutions |
JPS57206622A (en) | 1981-06-10 | 1982-12-18 | Ajinomoto Co Inc | Blood substitute |
US4532130A (en) | 1981-07-06 | 1985-07-30 | Rush-Presbyterian-St. Luke's Medical Center | Preparation of synthetic frythrocytes |
DE3130770C2 (de) | 1981-08-04 | 1986-06-19 | Biotest-Serum-Institut Gmbh, 6000 Frankfurt | Verfahren zur Gewinnung von hepatitissicheren, sterilen, pyrogenfreien und stromafreien Hämoglobinlösungen |
US4473496A (en) * | 1981-09-14 | 1984-09-25 | The United States Of America As Represented By The Secretary Of The Army | Intramolecularly crosslinked hemoglobin |
DE3144705C2 (de) | 1981-11-11 | 1983-12-08 | Biotest-Serum-Institut Gmbh, 6000 Frankfurt | Verfahren zur Herstellung eines lagerstabilen, vernetzten Hämoglobinpräparates mit hoher Sauerstoff-Transportkapazität, sowie das nach diesem Verfahren hergestellte Hämoglobinpräparat |
CH650647A5 (de) * | 1982-12-10 | 1985-08-15 | Knorr Naehrmittel Ag | Lagerfaehiges, zu einer dessert-mousse aufschlagbares produkt und verfahren zu dessen herstellung. |
US4473494A (en) | 1983-05-04 | 1984-09-25 | The United States Of America As Represented By The Secretary Of The Army | Preparation of stroma-free, non-heme protein-free hemoglobin |
US4529719A (en) * | 1983-05-04 | 1985-07-16 | Tye Ross W | Modified crosslinked stroma-free tetrameric hemoglobin |
GB8328917D0 (en) | 1983-10-28 | 1983-11-30 | Fisons Plc | Blood substitute |
US5281579A (en) | 1984-03-23 | 1994-01-25 | Baxter International Inc. | Purified virus-free hemoglobin solutions and method for making same |
US4831012A (en) | 1984-03-23 | 1989-05-16 | Baxter International Inc. | Purified hemoglobin solutions and method for making same |
DE3412144A1 (de) | 1984-03-31 | 1985-10-10 | Biotest Pharma GmbH, 6000 Frankfurt | Verfahren zur herstellung hochgereinigter, stromafreier, hepatitissicherer human- und tierhaemoglobinloesungen |
US4738952A (en) | 1984-04-27 | 1988-04-19 | Synthetic Blood Corporation | Substitute for human blood and a method of making the same |
US4598064A (en) | 1984-06-27 | 1986-07-01 | University Of Iowa Research Foundation | Alpha-alpha cross-linked hemoglobins |
US4600531A (en) * | 1984-06-27 | 1986-07-15 | University Of Iowa Research Foundation | Production of alpha-alpha cross-linked hemoglobins in high yield |
US4584130A (en) | 1985-03-29 | 1986-04-22 | University Of Maryland | Intramolecularly cross-linked hemoglobin and method of preparation |
DE3675588D1 (de) | 1985-06-19 | 1990-12-20 | Ajinomoto Kk | Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist. |
US5080885A (en) | 1986-01-14 | 1992-01-14 | Alliance Pharmaceutical Corp. | Brominated perfluorocarbon emulsions for internal animal use for contrast enhancement and oxygen transport |
US5077036A (en) | 1986-01-14 | 1991-12-31 | Alliance Pharmaceutical Corp. | Biocompatible stable fluorocarbon emulsions for contrast enhancement and oxygen transport comprising 40-125% wt./volume fluorocarbon combined with a phospholipid |
US4987154A (en) | 1986-01-14 | 1991-01-22 | Alliance Pharmaceutical Corp. | Biocompatible, stable and concentrated fluorocarbon emulsions for contrast enhancement and oxygen transport in internal animal use |
US5684050A (en) | 1986-01-24 | 1997-11-04 | Hemagen/Pfc | Stable emulsions of highly fluorinated organic compounds |
US4826811A (en) * | 1986-06-20 | 1989-05-02 | Northfield Laboratories, Inc. | Acellular red blood cell substitute |
US5464814A (en) | 1986-06-20 | 1995-11-07 | Northfield Laboratories, Inc. | Acellular red blood cell substitute |
US5194590A (en) * | 1986-06-20 | 1993-03-16 | Northfield Laboratories, Inc. | Acellular red blood cell substitute |
DE3620873A1 (de) | 1986-06-21 | 1987-12-23 | Rau Guenter | Vorrichtung zur bestimmung des partialdruckes von in einem fluid geloesten gasen und gasgemischen |
US4911929A (en) | 1986-08-29 | 1990-03-27 | The United States Of America As Represented By The Secretary Of The Navy | Blood substitute comprising liposome-encapsulated hemoglobin |
DE3636590A1 (de) | 1986-10-28 | 1988-05-26 | Braun Melsungen Ag | Blutersatzmittel |
US5084558A (en) | 1987-10-13 | 1992-01-28 | Biopure Corporation | Extra pure semi-synthetic blood substitute |
CA1312009C (en) * | 1986-11-10 | 1992-12-29 | Carl W. Rausch | Extra pure semi-synthetic blood substitute |
GB8710598D0 (en) * | 1987-05-05 | 1987-06-10 | Star Medical Diagnostics Ltd | Hemoglobin based blood substitute |
US5449759A (en) | 1987-05-16 | 1995-09-12 | Somatogen, Inc. | Hemoglobins with intersubunit desulfide bonds |
GB8711614D0 (en) * | 1987-05-16 | 1987-06-24 | Medical Res Council | Proteins |
US4861867A (en) | 1988-02-03 | 1989-08-29 | Baxter International, Inc. | Purified hemoglobin solutions and method for making same |
US4900780A (en) | 1988-05-25 | 1990-02-13 | Masonic Medical Research Laboratory | Acellular resuscitative fluid |
CA1338244C (en) | 1988-08-17 | 1996-04-09 | Xiang-Fu Wu | Purification of hemoglobin and methemoglobin by bioselective elution |
US5061688A (en) | 1988-08-19 | 1991-10-29 | Illinois Institute Of Technology | Hemoglobin multiple emulsion |
US5128452A (en) | 1989-04-19 | 1992-07-07 | Baxter International Inc. | Process for the production of crosslinked hemoglobin in the presence of sodium tripolyphosphate |
US5545727A (en) * | 1989-05-10 | 1996-08-13 | Somatogen, Inc. | DNA encoding fused di-alpha globins and production of pseudotetrameric hemoglobin |
US5599907A (en) | 1989-05-10 | 1997-02-04 | Somatogen, Inc. | Production and use of multimeric hemoglobins |
US5312808A (en) | 1989-11-22 | 1994-05-17 | Enzon, Inc. | Fractionation of polyalkylene oxide-conjugated hemoglobin solutions |
US5386014A (en) | 1989-11-22 | 1995-01-31 | Enzon, Inc. | Chemically modified hemoglobin as an effective, stable, non-immunogenic red blood cell substitute |
US5234903A (en) * | 1989-11-22 | 1993-08-10 | Enzon, Inc. | Chemically modified hemoglobin as an effective, stable non-immunogenic red blood cell substitute |
US5650388A (en) | 1989-11-22 | 1997-07-22 | Enzon, Inc. | Fractionated polyalkylene oxide-conjugated hemoglobin solutions |
US5478806A (en) | 1989-11-22 | 1995-12-26 | Enzon, Inc. | Enhancement of antitumor therapy with hemoglobin-based conjugates |
US5041615A (en) | 1989-12-05 | 1991-08-20 | Baxter International Inc. | Preparation of bis(salicyl) diesters |
US5239061A (en) | 1990-06-20 | 1993-08-24 | Research Corporation Technologies, Inc. | Modified human hemoglobin, blood substitutes containing the same, and vectors for expressing the modified hemoglobin |
US5352773A (en) | 1990-08-06 | 1994-10-04 | Baxter International Inc. | Stable hemoglobin based composition and method to store same |
US5248766A (en) | 1990-08-17 | 1993-09-28 | Baxter International Inc. | Oxirane-modified hemoglobin based composition |
US5114932A (en) | 1990-11-30 | 1992-05-19 | Runge Thomas M | Hyperosmolar oxyreplete hemosubstitute |
US5234555A (en) * | 1991-02-05 | 1993-08-10 | Ibbott Jack Kenneth | Method and apparatus for ionizing fluids utilizing a capacitive effect |
CA2066374C (en) | 1991-04-19 | 2002-01-29 | Paul E. Segall | Solution for perfusing primates |
US5295944A (en) | 1991-05-14 | 1994-03-22 | Dana-Farber Cancer Institute | Method for treating a tumor with ionizing radiation |
US5250665A (en) * | 1991-05-31 | 1993-10-05 | The University Of Toronto Innovations Foundation | Specifically β-β cross-linked hemoglobins and method of preparation |
US5334705A (en) | 1991-08-15 | 1994-08-02 | Duke University | Benzenetricarboxylate derivative-crosslinked low oxygen affinity hemoglobin |
US5349054A (en) | 1991-08-15 | 1994-09-20 | Duke University | Activated benzenepentacarboxylate-crosslinked low oxygen affinity hemoglobin |
US5334706A (en) | 1992-01-30 | 1994-08-02 | Baxter International | Administration of low dose hemoglobin to increase perfusion |
US5200323A (en) | 1992-01-31 | 1993-04-06 | Mcgill University | In vitro method to determine the safety of modified hemoglobin blood substitutes for human prior to clinical use |
US5296466A (en) | 1992-02-19 | 1994-03-22 | Board Of Regents, The University Of Texas System | Inhibition of nitric oxide-mediated hypotension and septic shock with iron-containing hemoprotein |
US5344393A (en) | 1992-02-28 | 1994-09-06 | Alliance Pharmaceutical Corp. | Use of synthetic oxygen carriers to facilitate oxygen delivery |
US5264555A (en) | 1992-07-14 | 1993-11-23 | Enzon, Inc. | Process for hemoglobin extraction and purification |
US5628930A (en) | 1992-10-27 | 1997-05-13 | Alliance Pharmaceutical Corp. | Stabilization of fluorocarbon emulsions |
US5558855A (en) | 1993-01-25 | 1996-09-24 | Sonus Pharmaceuticals | Phase shift colloids as ultrasound contrast agents |
US5635538A (en) | 1993-03-16 | 1997-06-03 | Alliance Pharmaceutical Corp. | Fluorocarbon emulsions with reduced pulmonary gas-trapping properties |
AU668294B2 (en) | 1993-03-16 | 1996-04-26 | Hemosol Inc. | Selective crosslinking of hemoglobins by oxidized, ring-opened saccharides |
US5554638A (en) | 1993-05-24 | 1996-09-10 | Duke University | Methods for improving therapeutic effectiveness of agents for the treatment of solid tumors and other disorders |
US5612310A (en) * | 1993-05-24 | 1997-03-18 | Duke University | Methods for improving therapeutic effectiveness of agents for the treatment of solid tumors and other disorders |
AU681675B2 (en) | 1993-06-04 | 1997-09-04 | Biotime, Inc. | Plasma-like solution |
US5407428A (en) | 1993-06-04 | 1995-04-18 | Biotime, Inc. | Solutions for use as plasma expanders and substitutes |
US5578564A (en) | 1993-07-23 | 1996-11-26 | Somatogen, Inc. | Nickel-free hemoglobin and methods for producing such hemoglobin |
TW381022B (en) | 1993-08-16 | 2000-02-01 | Hsia Jen Chang | Compositions and methods utilizing nitroxides to avoid oxygen toxicity, particularly in stabilized, polymerized, conjugated, or encapsulated hemoglobin used as a red cell substitute |
CA2106612C (en) | 1993-09-21 | 2001-02-06 | Diana Pliura | Displacement chromatography process |
US5545328A (en) | 1993-09-21 | 1996-08-13 | Hemosol Inc. | Purification of hemoglobin by displacement chromatography |
US5631219A (en) | 1994-03-08 | 1997-05-20 | Somatogen, Inc. | Method of stimulating hematopoiesis with hemoglobin |
US5585484A (en) * | 1995-04-19 | 1996-12-17 | Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University | Hemoglobin crosslinkers |
US5525630A (en) | 1995-06-01 | 1996-06-11 | Allos Therapeutics, Inc. | Treatment for carbon monoxide poisoning |
US5814601A (en) * | 1997-02-28 | 1998-09-29 | The Regents Of The University Of California | Methods and compositions for optimization of oxygen transport by cell-free systems |
DE69831248T2 (de) * | 1997-02-28 | 2006-04-13 | The Regents Of The University Of California, Oakland | Verfahren und zusammensetzungen zur optimierung des sauerstofftransportes in zellfreien systemen |
DE69824892D1 (de) | 1997-10-17 | 2004-08-05 | Univ California | System und verfahren zum charakterisieren von gastransporteigenschaften |
US5985825A (en) | 1998-02-28 | 1999-11-16 | The Regents Of The University Of California | Methods and compositions for optimization of oxygen transport by cell-free systems |
CA2233725A1 (en) * | 1998-03-31 | 1999-09-30 | Hemosol Inc. | Hemoglobin-hydroxyethyl starch complexes |
WO2003059287A2 (en) * | 2002-01-11 | 2003-07-24 | Sangart, Inc. | Methods and compositions for oxygen transport comprising an oxygen carrier and a crystalloid in hypertonic solution |
US7271145B2 (en) * | 2002-01-11 | 2007-09-18 | Sangart, Inc. | Methods and compositions for oxygen transport comprising modified hemoglobin in plasma |
US7501499B2 (en) * | 2002-12-23 | 2009-03-10 | Albert Einstein College Of Medicine Of Yeshiva University | Modified hemoglobin and methods of making same |
-
2002
- 2002-04-01 US US10/114,400 patent/US20030153491A1/en not_active Abandoned
-
2003
- 2003-01-10 ES ES03705713T patent/ES2299686T3/es not_active Expired - Lifetime
- 2003-01-10 CN CN038036487A patent/CN1630527B/zh not_active Expired - Fee Related
- 2003-01-10 BR BR0306846-3A patent/BR0306846A/pt not_active Application Discontinuation
- 2003-01-10 CA CA002473662A patent/CA2473662C/en not_active Expired - Lifetime
- 2003-01-10 PT PT03705713T patent/PT1465643E/pt unknown
- 2003-01-10 WO PCT/US2003/000696 patent/WO2003059363A1/en active IP Right Grant
- 2003-01-10 US US10/340,141 patent/US6844317B2/en not_active Expired - Lifetime
- 2003-01-10 EP EP03705713A patent/EP1465643B1/en not_active Expired - Lifetime
- 2003-01-10 KR KR1020047010847A patent/KR100964604B1/ko active IP Right Grant
- 2003-01-10 MX MXPA04006733A patent/MXPA04006733A/es active IP Right Grant
- 2003-01-10 DE DE60318388T patent/DE60318388T2/de not_active Expired - Lifetime
- 2003-01-10 CN CN2013100910214A patent/CN103203013A/zh active Pending
- 2003-01-10 JP JP2003559525A patent/JP5149480B2/ja not_active Expired - Fee Related
- 2003-01-10 AU AU2003207504A patent/AU2003207504B2/en not_active Ceased
- 2003-01-10 DK DK03705713T patent/DK1465643T3/da active
- 2003-01-10 AT AT03705713T patent/ATE382358T1/de active
-
2004
- 2004-08-24 US US10/925,067 patent/US6974795B2/en not_active Expired - Lifetime
-
2010
- 2010-03-09 JP JP2010052387A patent/JP2010138197A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
US20030162693A1 (en) | 2003-08-28 |
CN1630527B (zh) | 2013-04-24 |
US20030153491A1 (en) | 2003-08-14 |
US20050026816A1 (en) | 2005-02-03 |
JP2005515225A (ja) | 2005-05-26 |
EP1465643B1 (en) | 2008-01-02 |
DE60318388T2 (de) | 2008-12-24 |
EP1465643A4 (en) | 2004-10-20 |
AU2003207504B2 (en) | 2007-05-24 |
DE60318388D1 (de) | 2008-02-14 |
CN1630527A (zh) | 2005-06-22 |
KR20040081451A (ko) | 2004-09-21 |
DK1465643T3 (da) | 2008-05-13 |
JP2010138197A (ja) | 2010-06-24 |
CA2473662A1 (en) | 2003-07-24 |
AU2003207504A1 (en) | 2003-07-30 |
WO2003059363A1 (en) | 2003-07-24 |
EP1465643A1 (en) | 2004-10-13 |
CA2473662C (en) | 2009-12-22 |
BR0306846A (pt) | 2004-12-07 |
ATE382358T1 (de) | 2008-01-15 |
MXPA04006733A (es) | 2005-12-05 |
US6974795B2 (en) | 2005-12-13 |
CN103203013A (zh) | 2013-07-17 |
PT1465643E (pt) | 2008-03-27 |
US6844317B2 (en) | 2005-01-18 |
JP5149480B2 (ja) | 2013-02-20 |
ES2299686T3 (es) | 2008-06-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100964604B1 (ko) | 산소 친화도가 높은 개질된 헤모글로빈을 포함하는 산소 전달용 조성물 및 방법 | |
US9241979B2 (en) | Compositions for oxygen transport comprising a high oxygen affinity modified hemoglobin | |
US8278275B2 (en) | Method to enhance hemodynamic stability using oxygen carrying compositions | |
US7271145B2 (en) | Methods and compositions for oxygen transport comprising modified hemoglobin in plasma | |
EP1894573A2 (en) | Methods and compositions for oxygen transport comprising a high oxygen affinity |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E90F | Notification of reason for final refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20130524 Year of fee payment: 4 |
|
FPAY | Annual fee payment |
Payment date: 20141205 Year of fee payment: 5 |
|
FPAY | Annual fee payment |
Payment date: 20150619 Year of fee payment: 6 |
|
FPAY | Annual fee payment |
Payment date: 20160602 Year of fee payment: 7 |
|
FPAY | Annual fee payment |
Payment date: 20170621 Year of fee payment: 8 |
|
FPAY | Annual fee payment |
Payment date: 20180528 Year of fee payment: 9 |
|
FPAY | Annual fee payment |
Payment date: 20190530 Year of fee payment: 10 |